Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Autor: Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske

Publikováno v: The Lancet Haematology. 9:e810-e821

Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa4e06ca167ce956ab3c750cb5371c4d
https://doi.org/10.1016/s2352-3026(22)00263-0

985P Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors

Autor: Elke Jaeger, M-R. Rafiyan, Marina Schaaf, R. Eickhoff, S-E. Al-Batran, D. Kiselicki, M.W. Daniel, Thorsten Oliver Goetze, T. Habibzade

Publikováno v: Annals of Oncology. 32:S843

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e9fa726d65378ac6b7c9ffc74e1d388
https://doi.org/10.1016/j.annonc.2021.08.1369

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

1033P The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumours

Autor: C. Brignone, D. Kiselicki, M-R. Rafiyan, R. Eickhoff, Thorsten Oliver Goetze, S-E. Al-Batran, T. Habibzade, Elke Jäger, D.W. Müller

Publikováno v: Annals of Oncology. 31:S712

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fdf2f31c19371b381bc79c80a23f8388
https://doi.org/10.1016/j.annonc.2020.08.1153

Medikamentöse Behandlung des metastasierten Nierenzellkarzinoms

Autor: E. Jäger, M. R. Rafiyan

Publikováno v: DMW - Deutsche Medizinische Wochenschrift. 138:1567-1570

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6f9b987b1c4b9ecb5e9fbec177c74de
https://doi.org/10.1055/s-0033-1343291